ARTICLE | Clinical News
Lumiliximab regulatory update
January 21, 2008 8:00 AM UTC
EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for lumiliximab to treat chronic lymphocytic leukemia (CLL). The anti- CD23 mAb, which ...